Sector revisions Gilead Sciences, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 16/06/2025 BST			5-day change	1st Jan Change
110.83 ^USD	+0.77%		-1.45%	+19.98%

06-13	Gilead Sciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 11:20 AM
06-11	Gilead Sciences' Lenacapavir Provides 'Solid' Switching Opportunities for Current PrEP Users, RBC Says	MT

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility (Composite)	Nbr of analysts
	GILEAD SCIENCES, INC.							26
	ELI LILLY AND COMPANY							27
	JOHNSON & JOHNSON							23
	NOVO NORDISK A/S							22
	ABBVIE INC.							27
	ROCHE HOLDING AG							20
	NOVARTIS AG							19
	ASTRAZENECA PLC							20
	MERCK & CO., INC.							24
	AMGEN INC.							28
	PFIZER, INC.							23
	SANOFI							23
	VERTEX PHARMACEUTICALS INCORPORATED							28
	BRISTOL-MYERS SQUIBB COMPANY							22
	CHUGAI PHARMACEUTICAL CO., LTD.							14
	GSK PLC							19
	JIANGSU HENGRUI MEDICINE CO., LTD.							16
	HALEON PLC							17
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							17
	Average							22
	Weighted average by Cap.							23